FDA approves Novartis Vijoice® (alpelisib) as first and

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum...

Related Keywords

United States , New Jersey , East Hanover , America , Graham Jm Jr , Julie Masow , Kristen Davis , Sloan Simpson , Victor Bulto , Dan Connelly , Guillaume Canaud , Novartis Oncology Patient Support Program , Twitter , Novartis , Compassionate Use Programme , University Of Washington , Syndrome Community , Paris Descartes University , Institute Necker Enfants Malades , National Institutes Of Health , Drug Administration , Novartis Oncology Communications , Exchange Commission , Approval Program , Novartis Pharmaceuticals Corporation , Nj Novartis Pharmaceuticals Corporation , Novartis Pharmaceuticals Corp , Centre For Molecular Medicine , Related Overgrowth Spectrum , Accelerated Approval Program , Multichannel News Release , Executive Director , Necker Enfants Malades Hospital , Necker Enfants Malades , Molecular Medicine , Novartis Innovative Medicines , Patient Novartisoncology , National Institutes , Prescribing Information , Pharmaceuticals Corporation , Retrospective Chart Review Study , Patients With , Compassionate Use , Pharmaceuticals Corp , Media Relations ,